8-K: Terns Pharmaceuticals Announces CFO Transition and Interim Appointments

Terns Pharmaceuticals announces the departure of CFO Mark Vignola, Ph.D., effective February 1, 2025, and the appointment of interim replacements.

Summary

• Terns Pharmaceuticals announced the departure of Chief Financial Officer Mark Vignola, Ph.D., effective February 1, 2025.
• Mr. Vignola's departure was not due to any disagreement with the company's operations, policies, or practices.
• He has entered into a consulting agreement with the company, effective from February 1, 2025, through July 31, 2025.
• For the first two months of the consulting agreement, Dr. Vignola will receive $30,000 per month, and for the following two months, $15,000 per month.
• Amy Burroughs, the company's Chief Executive Officer, has assumed the role of principal financial officer on an interim basis.
• David Strauss, the company's Vice President of Finance and Controller, has assumed the role of principal accounting officer on an interim basis.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While a CFO departure can be concerning, the company has a transition plan in place and the departure was not due to disagreements.

Positives

• The transition appears amicable, with Dr. Vignola entering into a consulting agreement with the company.
• The company has appointed interim replacements for the CFO role, ensuring continuity in financial oversight.

Negatives

• The departure of a CFO can create uncertainty, even if the transition is planned.
• The company will incur additional costs related to the consulting agreement with Dr. Vignola.

Risks

• The interim appointments of the principal financial officer and principal accounting officer may create additional workload for Amy Burroughs and David Strauss.
• The company needs to find a permanent CFO to fill the role.

Future Outlook

The company will need to find a permanent CFO to replace Mark Vignola.

Management Comments

• Mr. Vignola's separation from employment was not the result of any disagreement with the Company's operations, policies or practices.

Industry Context

Executive transitions are common in the biopharmaceutical industry, especially for companies in the clinical stage. Companies often use consulting agreements to ensure a smooth transition and retain expertise.

Comparison to Industry Standards

• Interim CFO appointments are a common practice in the biopharmaceutical industry during executive transitions, similar to companies like Crinetics Pharmaceuticals who used consulting CEOs during their IPO.
• Consulting agreements are frequently used to retain expertise and ensure a smooth handover, as seen in other biotech firms undergoing leadership changes.

Management Changes

Related Party Transactions

• The consulting agreement between Terns Pharmaceuticals and Mark Vignola, Ph.D., is a related party transaction.

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CFO transition.
• Employees may experience changes in reporting structures during the interim period.

Next Steps

• Terns Pharmaceuticals will likely begin the search for a permanent Chief Financial Officer.
• The company will continue to rely on Amy Burroughs and David Strauss in their interim roles.

Key Dates

Keywords

CFO, transition, Terns Pharmaceuticals, financial officer, Amy Burroughs, David Strauss, consulting agreement, Mark Vignola, resignation